72716-80-4

Usage

Uses

Used in Pharmaceutical Industry:
5,6-DIMETHYL-2-OXO-1,2-DIHYDRO-PYRIDINE-3-CARBONITRILE is used as an intermediate in the synthesis of HIV-1 specific reverse transcriptase inhibitors. These inhibitors play a vital role in the treatment of HIV/AIDS by blocking the replication of the virus in the host cells.
5,6-DIMETHYL-2-OXO-1,2-DIHYDRO-PYRIDINE-3-CARBONITRILE is also used as an intermediate in the preparation of antiallergic agents. These agents are essential in the treatment of various allergic conditions, such as asthma, allergic rhinitis, and atopic dermatitis, by targeting the immune system's response to allergens.
Furthermore, 5,6-DIMETHYL-2-OXO-1,2-DIHYDRO-PYRIDINE-3-CARBONITRILE is utilized in the synthesis of Omeprazole metabolites. Omeprazole is a proton pump inhibitor commonly used to treat conditions related to excess stomach acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The metabolites of Omeprazole contribute to its therapeutic effects and help in managing the associated symptoms.

Upstream product

• 22428-91-7 2-methyl-3-oxobutanal 
• 109-77-3 malononitrile 
• 107-91-5 cyanoacetic acid amide 
• 143193-92-4 sodium 2‐methyl‐3‐oxobut‐1‐en‐1‐olate 
• 132247-74-6 2-methyl-3-oxo-1-butene 1-oxide sodium salt 
• 132247-74-6 (E)-4-hydroxy-3-methylbut-3-en-2-one sodium salt 
• 78-93-3 butanone 
• 109-94-4 formic acid ethyl ester 
• 110-89-4 piperidine 
• 64-17-5 ethanol 
• 50421-80-2 4-hydroxy-3-methyl-but-3-en-2-one 

Downstream Products

• 65176-93-4 2-chloro-5,6-dimethylpyridine-3-carbonitrile 
• 27992-31-0 5,6-dimethyl-pyridin-2-ol 
• 51727-05-0 5,6-dimethyl-2-hydroxynicotinic acid 
• 113124-06-4 2-bromo-5,6-dimethyl-3-pyridinecarbonitrile 
• 441304-12-7 5,6-dimethyl-3-[[ethoxy(thiocarbonyl)]thio]-2-methoxypyridine 
• 51727-05-0 5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 113124-09-7 5,6-dimethyl-3-pyridinecarbonitrile 
• 98276-88-1 3-nitro-5,6-dimethyl-2(1H)-pyridinone 
• 65213-96-9 2,3-dimethyl-6-chloro-5-nitropyridine 
• 858338-82-6 N-[4-(3,5-dimethyl-benzyl)-2-methoxy-5,6-dimethyl-pyridin-3-yl]-2,2-dimethyl-propionamide 
• 847741-02-0 N-[2-methoxy-5,6-dimethyl-4-(3-methylbenzoyl)pyridin-3-yl]-2,2-dimethylpropionamide 
• 847741-01-9 N-[4-((3-methylphenyl)hydroxymethyl)-2-methoxy-5,6-dimethylpyridin-3-yl]-2,2-dimethylpropionamide 
• 248247-23-6 3-amino-4-(3,5-dimethyl-benzyl)-5,6-dimethyl-1H-pyridin-2-one 
• 248247-85-0 3-amino-5,6-dimethyl-4-(3-methylbenzoyl)pyridin-2(1H)-one 

Relevant academic research and scientific papers

Synthesis, Neurotropic Activity, and Molecular Docking of New Condensed Thieno[2,3-b]pyridine Derivatives

Abstract: Methods for the preparation of new condensed derivatives of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines based on 5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile were developed. Substitution reactions in the 3rd and 4th positions of 7,8-dimethylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one were conducted. The neurotropic activity of 12 obtained compounds was studied in vivo in rats and mice. Eight compounds were found to have an anticonvulsant effect of antagonism with corazole. Four selected compounds had anxiolytic and behavior activating effects. Molecular docking of the synthesized compounds was performed to predict their interaction with the GABAA receptor. Five compounds were identified, the complexation of which with the GABAA receptor occurs in two places: the benzamidine site of subsite 1 and subsite 3 of the ECD interface, which indicates the inhibitory effect of the compounds on the target.

Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents

Zeste enhancer homolog 2 (EZH2) is highly expressed in various malignant tumors, which could silence tumor suppressor genes via trimethylation of H3K27. Herein was first reported a novel series of pyrrole-3-carboxamide derivatives carrying a pyridone fragment as EZH2 inhibitors. By combining computational modeling, in vitro cellular assays and further rational structure-activity relationship exploration and optimization, compound DM-01 showed powerful inhibition towards EZH2. DM-01 was found to have significant ability to reduce the cellular H3K27me3 level in K562 cells in the Western blot test. Meanwhile, our data showed that knockdown EZH2 in A549 cells resulted in a decrease of cell sensitivity to DM-01 at 50 and 100 μM. DM-01 could also increase the transcription expression of DIRAS3 in a dose-dependent manner, a tumor suppressor in the downstream of EZH2, suggesting it was worth investigating further as a lead compound.

Pyrrole-3-formamide compound as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to a pyrrole-3-formamide compound as well as a preparation method and application thereof, in particular to a pyrrole-3-formamidecompound shown as a formula (I) or (II) and a pharmaceutically-acceptable salt thereof, wherein R to R and X are defined in the claims and description. The preparation of the compound mainly comprises performing Knorr pyrrole synthesis, Hantzsch pyrrole synthesis, decarboxylation, alkylation, hydrolysis, condensation, cyclization and reduction on ethyl acetoacetate or tert-butyl acetoacetate serving as the raw material. The pyrrole-3-formamide compound and the pharmaceutically-acceptable salt thereof have good treatment effects on tumors, and can be applied to the preparation of anti-tumor drugs. (The formulas (I) and (II) are shown in the description).

Preparation process of 5,6-dimethyl-2-hydroxynicotinic acid

The invention provides a preparation process of 5,6-dimethyl-2-hydroxynicotinic acid 1. The preparation process of 5,6-dimethyl-2-hydroxynicotinic acid comprises the following steps: 1) performing a reaction on 2-butanone and ethyl formate in a proper solvent, under the existence of alkali and at proper temperature to obtain a compound 2; 2) performing condensation on the compound 2 and cyanoacetamide in a proper solvent and at proper temperature to obtain a compound 3; and 3) performing cyan-hydrolysis on the compound 3 under the existence of diluted acid to obtain 5,6-dimethyl-2-hydroxynicotinic acid 1. The synthesis route is as shown in the description. In the preparation process, the raw materials, the reagents and the solvents are the conventional synthesis reagents, and are cheap andeasily available; and the reaction condition of each step is mild, the aftertreatment operation is simple, the reaction yield is high and the product purity is high. The whole preparation cost of theproducts is low and the industrial production requirement is met.

Zinc (II)-mediated selective O-benzylation of 2-Oxo-1,2-dihydropyridines systems

The selective O-benzylation of 2-oxo-1,2-dihydropyridines plays a critical role in organic synthesis of natural products and biological active molecules. Herein we report a novel ternary system of ZnO, ZnCl2 and N,N-diisopropylethylamine (DIEA), that is highly effective for selective O-benzylation of 2-oxo-1,2-dihydropyridines using abundant substituted benzyl halides and related substituted 2-oxo-1,2-dihydropyridines compounds. This process allows access to a variety of O-benzyl products under mild reaction conditions, which are important synthetic intermediates in the protection of functional groups, and represents a new method toward the development for the O-benzylation of 2-oxo-1,2-dihydropyridines.

Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress

The invention relates to the use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress. The invention also relates to the use of substituted pyridone carboxamides of general formula (I) or the salts thereof, the groups in general formula (I) corresponding to the definitions cited in the description, for increasing the stress tolerance of plants to abiotic stress, for strengthening plant growth and/or for increasing the plant yield. The invention further relates to specific methods for producing said compounds.

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS

The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

ANTIPRURITICS

It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.